Greater Occipital Nerve Block
7
2
3
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
Greater Occipital Nerve Block for Migraine With Medication Overuse Headache
Botulinum Toxin and/or Greater Occipital Nerve Block for Patients With Chronic Migraine
Treatment Response in Patients With Medication-Overuse Headache
The Effect of Interventional Procedures on Serum CGRP and PACAP-38 Levels in Chronic Migraine
Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Migraine
Greater Occipital Nerve Blockade and Sphenopalatine Ganglion Blockade in Patients With Episodic Migraine
Chronic Migraine Prophylaxis: Ultrasound-Guided Greater Occipital Nerve Block Versus Medical Treatment